Wall Street Zen Upgrades Intellia Therapeutics (NASDAQ:NTLA) to “Hold”

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

NTLA has been the topic of a number of other reports. Barclays decreased their price objective on Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating on the stock in a report on Friday, November 7th. Canaccord Genuity Group cut their price objective on shares of Intellia Therapeutics from $54.00 to $48.00 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Bank of America reiterated a “neutral” rating on shares of Intellia Therapeutics in a research note on Monday, March 2nd. Evercore set a $8.00 price objective on Intellia Therapeutics and gave the company an “in-line” rating in a report on Tuesday, November 11th. Finally, Wedbush dropped their price target on Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Eleven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Intellia Therapeutics presently has a consensus rating of “Hold” and an average price target of $19.59.

Intellia Therapeutics Stock Up 2.2%

Intellia Therapeutics stock opened at $13.44 on Friday. The company’s 50-day moving average price is $12.33 and its two-hundred day moving average price is $13.16. The stock has a market cap of $1.59 billion, a P/E ratio of -3.51 and a beta of 2.09. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The company had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. During the same quarter in the previous year, the company posted ($1.27) earnings per share. The business’s revenue was up 78.4% on a year-over-year basis. Equities analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Insider Transactions at Intellia Therapeutics

In related news, EVP James Basta sold 10,397 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $95,756.37. Following the completion of the transaction, the executive vice president owned 101,528 shares in the company, valued at $935,072.88. This trade represents a 9.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the transaction, the executive vice president directly owned 98,533 shares of the company’s stock, valued at $907,488.93. The trade was a 7.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 53,051 shares of company stock worth $488,600. Corporate insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds have recently made changes to their positions in the stock. Comerica Bank raised its holdings in Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after purchasing an additional 901 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Intellia Therapeutics during the 2nd quarter worth about $26,000. Blue Bell Private Wealth Management LLC acquired a new position in shares of Intellia Therapeutics in the 3rd quarter valued at about $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in Intellia Therapeutics during the third quarter worth approximately $30,000. Finally, Advisory Services Network LLC acquired a new position in Intellia Therapeutics in the third quarter valued at approximately $33,000. 88.77% of the stock is currently owned by institutional investors.

More Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Jefferies (or another firm) boosted its price target to $30, a sizable upward revision that supports upside expectations for NTLA. Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $30.00
• Positive Sentiment: A separate analyst raised the price target to $28, reinforcing bullish momentum from multiple houses. Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $28.00
• Positive Sentiment: Leerink Partners published a note saying NTLA’s stock price is expected to rise, adding another bullish voice that can attract momentum buyers. Intellia Therapeutics (NASDAQ:NTLA) Stock Price Expected to Rise, Leerink Partners Analyst Says
• Positive Sentiment: Wells Fargo reiterated a strong forecast for price appreciation, supporting investor confidence in NTLA’s longer-term prospects. Wells Fargo & Company Forecasts Strong Price Appreciation for Intellia Therapeutics (NASDAQ:NTLA) Stock
• Positive Sentiment: Royal Bank of Canada raised its target to $15, another incremental upgrade that may help lift consensus sentiment. Royal Bank Of Canada Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $15.00
• Neutral Sentiment: Intellia announced inducement equity grants to six new employees under its 2024 Inducement Plan — routine hiring news that signals talent additions but also dilution/cost. Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Neutral Sentiment: Analysts’ consensus rating sits at “Hold,” indicating mixed professional views despite recent bullish notes. Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of “Hold” from Analysts
• Neutral Sentiment: A valuation/deep-dive piece reviews NTLA’s rebound and financials (revenue growth vs. large losses), useful context for longer-term investors but not a near-term catalyst. A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound
• Negative Sentiment: HC Wainwright lowered its earnings estimates for NTLA, a negative data point that may weigh on near-term expectations. HC Wainwright Brokers Reduce Earnings Estimates for NTLA
• Negative Sentiment: Canaccord Genuity trimmed its outlook for NTLA, adding to the minority of bearish analyst moves. Canaccord Genuity Group Has Lowered Expectations for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.